Reading the annual reports…

First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.

AAPG · Nasdaq · United States · Pharmaceutical Preparations

ASCENTAGE PHARMA GROUP INTERNATIONAL

Suzhou , Jiangsu · Fiscal year ends in December · Figures in CNY

+ Add to watchlist Compare

In shortASCENTAGE PHARMA GROUP INTERNATIONAL is loss-making, burns cash and carries heavy debt, with revenue growing (+341.8% last year).

Financial health

Weak

Built from five areas over the last five annual reports. Tap an area to see the figures behind it.

How is this score calculated? →

Profitability0

Operating marginShare of each sale left after running the business, before interest and tax.	–	n/a
Net marginShare of each sale left as profit after every cost, interest and tax.	-41.3%	0/100
Return on equityProfit earned on the money shareholders put in. Above 15% is strong.	-249.8%	0/100
Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge.	–	n/a

Weight in the score: 25%

Balance sheet20

Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash.	1.26×	39/100
Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted.	6.32×	0/100
Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable.	–	n/a
Interest coverageHow many times operating profit covers interest. Below 2 is risky.	–	n/a
Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress.	–	n/a

Weight in the score: 25%

Cash generation0

Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt.	-13.8%	0/100
Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy.	–	n/a
Years with positive free cash flow (last 5)	0 of 3	0/100

Weight in the score: 20%

Stability33
Profitable years (last 5) 0 of 3 0/100
Years of revenue decline (last 5) 0 of 2 100/100
Revenue growth volatility 237.5% 0/100
Operating margin volatility – n/a
Weight in the score: 20%
Growth–
Revenue growth, 3-year average – n/a
EPS growth, 3-year average – n/a
Weight in the score: 10%

Profitable years (last 5)	0 of 3	0/100
Years of revenue decline (last 5)	0 of 2	100/100
Revenue growth volatility	237.5%	0/100
Operating margin volatility	–	n/a

Revenue growth, 3-year average	–	n/a
EPS growth, 3-year average	–	n/a

Fiscal year 2024 · change vs prior year

Revenue: ¥980.7M; ▲ 341.8%
Net income: −¥405.4M; ▲ 56.2%
Free cash flow: −¥135.6M; ▲ 82.4%
Operating margin: –; –
Cash & investments: ¥893.1M; –
Total debt: ¥1.7B; ▼ 7.1%
Diluted EPS: −¥1.34; ▲ 59.1%
Return on equity: −249.8%; –

Trends

Annual figures as reported. Hover a bar or point for the exact value.

Revenue and net income

RevenueNet income

Margins

Statements

The last 3 fiscal years from the company's annual reports.

CNY millions; negative values in parentheses.

Fiscal year	FY22	FY23	FY24
Revenue	210	222	981
Cost of revenue	22	31	29
Gross profit	188	191	952
Research & development	743	707	947
Interest expense	53	96	64
Pre-tax income	(887)	(933)	(395)
Income tax	(4.2)	(7.2)	10
Net income	(883)	(926)	(405)
Diluted EPS	−¥3.35	−¥3.28	−¥1.34
Diluted shares (millions)	264	282	302

Export to Excel · Investor plan PDF report · Pro plan

Risk checks

Altman Z'' score

Not computed: a required balance-sheet item is missing.

Piotroski F-score

Not computed: it needs two consecutive complete years.

Sources

20-FPeriod ending Dec 31, 2025Filed Apr 29, 2026Open the report ↗
20-FPeriod ending Dec 31, 2024Filed Apr 16, 2025Open the report ↗

All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works

Latest annual report: Dec 31, 2025 · Data updated Apr 16, 2025

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) financial health, profit and balance sheet · Scorvest